GOVERNMENT COUNSEL, LLC for APOTEX CORPORATION
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
S.2910 - Expanding Access to Low-Cost Generics Act of 2021; S. 2740-Promoting Readiness and Ensuring Proper Active Pharmaceutical Ingredient Reserves of Essential Medicines (PREPARE) Act.
Foreign entity interest: Aposherm Inc. and Apotex Holdings Inc., parent companies of Apotex Corp. identified on the LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HENRY W MENN | Chief of Staff, Sen. Bob Graham; Minority Staff Director & Counsel, Sen. Cmte on Veterans Affairs; Sp. Asst. Legislative Affairs, FDA Office of Commissioner. |
Manufacturing MAN
Americas Supply Chains Executive Order 14017 of Feb 24, 2021 [86 Fed. Reg. 11849 (March 1, 2021)]. Policies relating to strengthening domestic manufacturing of active pharmaceutical ingredients and finished dosages.
Foreign entity interest: Aposherm Inc. and Apotex Holdings Inc., parent companies of Apotex Corp. identified on the LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HENRY W MENN | Chief of Staff, Sen. Bob Graham; Minority Staff Director & Counsel, Sen. Cmte on Veterans Affairs; Sp. Asst. Legislative Affairs, FDA Office of Commissioner. |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.